Kaushik Raval, MD
Psychiatry · Saginaw, MINPI 1801995576
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,320 of the $56,127 with a category attached, or 80.7%. Supernus Pharmaceuticals, Inc. accounts for 61.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $26,001 and has fallen 99.2% since, to $208 in 2025. Among psychiatry clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $208.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$35K
- Johnson & Johnson$17K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- Sunovion Pharmaceuticals Inc.$640
- Alkermes, Inc.$533
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$45,32081%
- Travel & lodging$3,6176%
- Food & beverage$7,19013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 67 | $34,586 |
| Johnson & Johnson | 58 | $17,030 |
| Otsuka America Pharmaceutical, Inc. | 23 | $1,097 |
| Lundbeck LLC | 38 | $1,018 |
| Sunovion Pharmaceuticals Inc. | 31 | $640 |
| Alkermes, Inc. | 19 | $533 |
| AbbVie(2 entities) | 11 | $410 |
| Neurocrine Biosciences, Inc. | 3 | $257 |
| Teva Pharmaceuticals USA, Inc. | 3 | $142 |
| Jazz Pharmaceuticals Inc. | 4 | $129 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $82 |
| Avanir Pharmaceuticals, Inc. | 1 | $60 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Indivior Inc. | 1 | $28 |
| Angiodynamics, Inc. | 1 | $28 |
| Janssen Scientific Affairs, LLC | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$31,481
- INVEGA SUSTENNA$15,779
- INVEGA TRINZA$15,099
- INGREZZA$245
- REXULTI$220
- VIIBRYD$200
- SPRAVATO$115
- AUSTEDO$100
How this compares
$56,127 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 29 | $67,117 |
| Abilify MaintenaAripiprazole | 21 | $57,406 |
| RexultiBrexpiprazole | 18 | $32,503 |
| TrintellixVortioxetine Hydrobromide | 28 | $16,100 |
| Lurasidone Hcl | 17 | $5,059 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 28 | $1,010 |
| Duloxetine Hcl | 58 | $993 |
| Bupropion XlBupropion Hcl | 81 | $919 |
| Clonazepam | 108 | $878 |
| Dextroamphetamine Sulfate | 11 | $804 |
| Lamotrigine | 83 | $797 |
| Doxepin Hcl | 31 | $794 |
| Ziprasidone Hcl | 30 | $743 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $679 |
| Quetiapine Fumarate | 60 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,097 | $89,90939 claims |
| Johnson & JohnsonInvega Sustenna | $17,030 | $67,11729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in Saginaw
- Andreas SidiropoulasDetroit$2.8M
- Welton WashingtonYpsilanti$1.4M
- Joel YoungRochester Hills$1.1M
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Robert LagrouClarkston$267K
- Michael IngramBay City$255K
- Samuel WedesLivonia$158K
- Arash JavanbakhtDetroit$102K
- Theodore RuzaWest Bloomfield$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.